Jo Ann Rinaudo
National Institutes of Health
CancerInternal medicineOncologyIntensive care medicineStage (cooking)Prospective cohort studyCohort studyPancreatitisCirrhosisHepatocellular carcinomaPancreasDiseasePancreatic cancerHepatitis B virusBiorepositoryEarly detectionGene isoformDiabetes mellitusMedicineCohortBiomarker (medicine)Gastroenterology
32Publications
14H-index
528Citations
Publications 29
Newest
#1Jose Serrano (NIH: National Institutes of Health)H-Index: 49
#2Jo Ann RinaudoH-Index: 14
Last. Dana K. AndersenH-Index: 21
view all 6 authors...
PURPOSE OF REVIEW Diseases of the pancreas are a broad spectrum of conditions resulting from metabolic, inflammatory, and neoplastic processes (pancreatitis, pancreatogenic diabetes, and pancreatic cancers). Pancreatic diseases cause significant morbidity, mortality, and cost. RECENT FINDINGS Research progress in diseases of the exocrine pancreas (chronic pancreatitis [CP], pancreatogenic diabetes mellitus, and pancreatic cancer) has been hampered by the disorders' heterogeneity, the limitations...
Source
#1Amit G. Singal (UTSW: University of Texas Southwestern Medical Center)H-Index: 62
#2Yujin Hoshida (UTSW: University of Texas Southwestern Medical Center)H-Index: 64
Last. Augusto Villanueva (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 63
view all 15 authors...
Source
#1Zobeida Cruz-Monserrate (The Ohio State University Wexner Medical Center)H-Index: 21
#2Kristyn Gumpper (The Ohio State University Wexner Medical Center)H-Index: 9
Last. Darwin L. Conwell (The Ohio State University Wexner Medical Center)H-Index: 53
view all 19 authors...
Abstract Background Chronic pancreatitis (CP) does not have diagnostic or prognostic biomarkers. CP is the end stage of a progressive inflammatory syndrome that is diagnosed at late stages by morphologic features. To diagnose earlier stages of the disease, a new mechanistic definition was established based on identifying underlying pathogenic processes and biomarker evidence of disease activity and stage. Although multiple risk factors are known, the corresponding biomarkers needed to make a hig...
Source
#1Matthew R. Young (NIH: National Institutes of Health)H-Index: 34
#2Natalie AbramsH-Index: 5
Last. Sudhir SrivastavaH-Index: 58
view all 6 authors...
Pancreatic cancer continues to be one of the deadliest malignancies and is the third leading cause of cancer-related mortality in the United States. Based on several models, it is projected to become the second leading cause of cancer-related deaths by 2030. Although the overall survival rate for patients diagnosed with pancreatic cancer is less than 10%, survival rates are increasing in those whose cancers are detected at an early stage, when intervention is possible. There are, however, no rel...
1 CitationsSource
#1Ying Liu (Van Andel Institute)H-Index: 7
#2Sukhwinder Kaur (UNMC: University of Nebraska Medical Center)H-Index: 15
Last. Brian B. Haab (Van Andel Institute)H-Index: 38
view all 11 authors...
Background. Patients afflicted with pancreatic ductal adenocarcinoma (PDAC) face a dismal prognosis, but headway could be made if physicians could identify the disease earlier. A compelling strategy to broaden the use of surveillance for PDAC is to incorporate molecular biomarkers in combination with clinical analysis and imaging tools. Methods. This article summarizes the components involved in accomplishing biomarker validation and an analysis of the requirements of molecular biomarkers for di...
2 CitationsSource
#1Dhiraj YadavH-Index: 52
Last. Darwin L. ConwellH-Index: 53
view all 14 authors...
Source
Last. Bechien U. WuH-Index: 23
view all 11 authors...
Background: New-onset hyperglycemia may suggest presence of occult pancreatic cancer The aim of this pilot study was to assess feasibility of pancreatic imaging in patients enrolled in the prospective NOD cohort study Methods:We conducted a prospective pilot study November 2018-April 2020 within Kaiser Permanente Southern California Patients 50-85 years enrolled in the NOD study (newly elevated glycemic parameter, no history of diabetes) were invited to complete a three-phase contrast-enhanced c...
#1Matthew R. YoungH-Index: 34
#2Natalie AbramsH-Index: 5
Last. Sudhir SrivastavaH-Index: 58
view all 6 authors...
Pancreatic cancer is the fourth leading cause of cancer death in the United States and the 5-year relative survival for patients diagnosed with pancreatic cancer is less than 10%. Early intervention is the key to a better survival outcome. Currently, there are no biomarkers that can reliably detect pancreatic cancer at an early stage or identify precursors that are destined to progress to malignancy. The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection was formed under ...
Source
#1Ju Dong Yang (Mayo Clinic)H-Index: 32
#2Benyam D. Addissie (Mayo Clinic)H-Index: 7
Last. Lewis R. Roberts (Mayo Clinic)H-Index: 84
view all 31 authors...
Background/Aim: The GALAD score is a serum biomarker-based model that predicts the probability of having hepatocellular carcinoma (HCC) in patients with chronic liver disease. We aimed to assess the performance of the GALAD score in comparison to liver ultrasound for detection of HCC. Methods: A single center cohort of 111 HCC and 180 controls with cirrhosis or chronic hepatitis B and a multicenter cohort of 233 early HCC and 412 cirrhosis patients from the Early Detection Research Network (EDRN...
35 CitationsSource
#1elly A. Borges (UPenn: University of Pennsylvania)H-Index: 1
#2Jianliang Dai (Fred Hutchinson Cancer Research Center)H-Index: 9
Last. K. Rajender Reddy (UPenn: University of Pennsylvania)H-Index: 95
view all 12 authors...
Abstract Background Hepatocellular carcinoma (HCC) is a common malignancy with a steadily rising incidence and associated morbidity and mortality. Cirrhosis of the liver is presently the leading risk factor for developing HCC. Abdominal imaging, with or without alpha-fetoprotein (AFP) testing, every 6 months is the current surveillance strategy for patients at risk. The available biomarkers for detecting this cancer at an early stage have inadequate sensitivity and specificity. Methods The Hepat...
3 CitationsSource